\xe2\x80\xa2 Handling analysis on all required biological, chemical and raw materials to ensure safety requirements are met. \xe2\x80\xa2 Providing and maintaining relevant documentation and records on each testing. \xe2\x80\xa2 Monitoring and directing the all necessary tests on Quality. \xe2\x80\xa2 Investigating and solving problems that arise by providing with restorative actions and formal responses. \xe2\x80\xa2 Ensuring materials are not contaminated by agents from environment or starting material. \xe2\x80\xa2 Detect and record down any possible defects or errors in the product,. \xe2\x80\xa2 Testing on all incoming and outgoing materials and products. \xe2\x80\xa2 Necessary reports that highlight issues and possible improvements to Quality Control Supervisor. \xe2\x80\xa2 Assign tasks to Quality Control Technicians \xe2\x80\xa2 To report to the superior in a timely manner \xe2\x80\xa2 To attend ad-hoc request Requirements \xe2\x80\xa2 Candidate must possess Bachelor Of Science Microbiology & Molecular Genetics \xe2\x80\xa2 Fast learner, persistent with good organizational, analytical and interpersonal skills \xe2\x80\xa2 Willing to work beyond office hours when needs arise \xe2\x80\xa2 Good communication skills and interpersonal skills
SGB has incorporated a new wholly-owned subsidiary, Solution Biologics Sdn. Bhd., to undertake the supply of vaccines and biologics. For the initial phase of the business, Solution Biologics Sdn. Bhd will operates a fill and finish facility dedicated to vaccines and biologics. The facility will be housed in the current manufacturing building at Technology Park Malaysia and expected to be operational by first quarter of 2021. Biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare. The annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Currently, more than 350 biologics are commercially presented in the biopharmaceuticals market. Since biologics are quite large in comparison to chemical-based drugs and made up of proteins, they require extra care to maintain their size, shape, form, and stability. These factors correlate to the intended effect and efficiency of the biologic drug. We are committed to developing newer and more effective vaccines and biologics through research and development programme with our partners. Our plan for the future will include paediatric and adult vaccines that are part of the National Immunisation Schedule of Malaysia and the Extended Programme of Immunisation (EPI) of various countries in the region.
Bachelor\'s or Equivalent